Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79

3 months ago Leukemia , CAR-T , patient story

China’s CAR-T Therapy: A Beacon of Hope for Children with Acute Lymphoblastic Leukemia (ALL)

#CARTTherapy #Leukemia #ChildhoodCancer #ALL #CART #AcuteLymphoblasticLeukemia #Patientstory

China’s CAR-T cell therapy is emerging as a beacon of hope in the fight against cancer, bringing unprecedented treatment possibilities. As a precise cellular immunotherapy, CAR-T therapy enhances the cancer-fighting abilities of T-cells through genetic editing technology, offering breakthroughs for patients with cancers resistant to traditional treatments, especially in blood cancers like leukemia.

From Diagnosis to Treatment: Strength and Struggle

Shan is a young child in China who has endured long-term treatment for leukemia. Diagnosed with acute lymphoblastic leukemia (ALL) in 2019, this news brought immense suffering to her and her family, as she was only five years old. Although ALL generally responds well to chemotherapy, Shan’s cancer cells persisted stubbornly after several rounds of chemotherapy, failing to reach full remission. Her doctors recommended a bone marrow transplant, but due to physical and family constraints, she had to opt for conservative treatment. Nevertheless, Shan did not give up her desire to live, showing remarkable resilience over five years.

A New Hope Through CAR-T Therapy

In 2023, Shan’s condition worsened as her anemia grew severe, with her hemoglobin levels dropping to a critical point. Faced with despair, her mother reached out to our team at Advanced Medicine in China, where experts quickly admitted her to the hospital. After a comprehensive evaluation, our hematology-oncology specialists decided to proceed with CAR-T therapy for her.

Following a thorough process of gene modification and the infusion of CAR-T cells, Shan’s condition improved rapidly. In the early stages of treatment, her complexion brightened, her energy levels noticeably improved, and subsequent tests showed that her tumor cells had completely disappeared, achieving clinical remission. Shan was finally free from the shadow of cancer, gradually regaining the joy and health of childhood.

A Medical Breakthrough: New Hope for Children with Leukemia

Shan’s success story signifies the maturation of CAR-T therapy in China, showcasing its powerful potential, particularly in treating refractory and relapsed childhood acute leukemia. In recent years, Chinese medical teams have actively adopted CAR-T technology in treating pediatric blood cancers, achieving remarkable long-term remission for many children. As the country with the highest number of CAR-T therapy applications globally, China’s hospital teams possess extensive experience and advanced technological capabilities, offering high-quality treatment to more children suffering from relapsed and refractory blood diseases.

Moving Forward: A Promising Future for Cellular Immunotherapy

With the continued development of CAR-T therapy in China, more patients with challenging cancers stand to benefit. Shan’s recovery is not only a family’s joy but also a testament to China’s medical progress. CAR-T therapy is ushering in a new era of cellular immunotherapy, giving more patients the possibility of life extension and recovery.

🎉🎉To assess whether the condition is suitable for CAR-T therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of <Advanced Medicine in China> for preliminary evaluation!

WhatsApp: Https://wa.me/+861371795907

Email: doctor.huang@globecancer.com

#CancerResearch #MedicalBreakthrough #Immunotherapy #ChinaMedicine #Oncology #CancerHope #LeukemiaAwareness #CancerTreatment

3 months ago Leukemia , CAR-T

Another New CAR-T Therapy in China is Fast-Tracking Approval, Targeting Pediatric Acute Lymphoblastic Leukemia(ALL) with a 100% Response Rate!

Another New CAR-T Therapy in China is Fast-Tracking Approval, Targeting Pediatric Acute Lymphoblastic Leukemia with a 100% Response Rate!

ALL

#ALL #AcuteLymphoblasticLeukemia #Leukemia #CART #CARTtherapy

In recent years, CAR-T cell therapies from China have garnered global attention in the fight against cancer, and now another CAR-T product is about to hit the market. Priscabtagene Autoleucel Injection (pCAR-19B), developed by China’s Precision Biotech, is specifically designed for relapsed or refractory B-cell acute lymphoblastic leukemia (ALL) and is currently under priority review for approval. It is poised to become China’s first CAR-T therapy specifically tailored for children and adolescents with acute leukemia.

This groundbreaking therapy has shown remarkable efficacy, achieving a 100% overall response rate in early clinical trials. For patients who no longer respond to conventional treatments, Priscabtagene Autoleucel offers a new lifeline. The therapy has demonstrated superior safety and efficacy in clinical settings, thanks to gene optimization and advanced vector systems that reduce side effects while enhancing effectiveness.

Currently, pCAR-19B has entered Phase II clinical trials, expanding its scope beyond children to include adult patients with relapsed leukemia. It is also being researched for the treatment of other malignant lymphomas, such as diffuse large B-cell lymphoma and follicular lymphoma. This signifies the vast potential of CAR-T therapies in China, promising more effective treatment options for blood cancer patients both domestically and globally.

Precision Biotech’s CAR-T therapy is expected to gain approval soon, contributing to global medical innovation while bringing new hope to countless patients.

To assess whether the condition is suitable for CAR-T therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of Advanced Medicine in China for preliminary evaluation!

WhatsApp: Https://wa.me/+8613717959070

Email: doctor.huang@globecancer.com

#ChinaCAR_T #PediatricLeukemia #CancerTherapy #PrecisionBiotech #CAR_TInnovation #LeukemiaTreatment #CancerBreakthrough #GlobalHealthcare #BloodCancerTreatment #MedicalAdvancement #Immunotherapy #ChildhoodCancer

7 months ago CAR-T , Leukemia

Chinese Hospital’s CAR-T Therapy Saves the Life of a Ph+ Acute Lymphoblastic Leukemia Patient

### Chinese Hospital’s CAR-T Therapy Saves the Life of a Ph+ Acute Lymphoblastic Leukemia Patient | Successful Case from The First Affiliated Hospital of Chongqing Medical University

CAR-T Therapy

On November 7, 2023, China’s first CAR-T product for treating adult leukemia, Yuan Ruida (Inaticabtagene Autoleucel Injection), was officially approved for market release. This marks a significant breakthrough in the field of leukemia cellular immunotherapy in China. Recently, The First Affiliated Hospital of Chongqing Medical University successfully treated a young patient with Philadelphia chromosome-positive (Ph+) B-cell acute lymphoblastic leukemia (B-ALL), demonstrating the remarkable efficacy of this innovative therapy.

Successful Case

The patient, a 20-year-old female, was diagnosed with Ph+ B-ALL in early 2021. Despite undergoing tyrosine kinase inhibitors (TKI) combined with chemotherapy and hematopoietic stem cell transplantation (HSCT), her disease relapsed multiple times. Finally, she tried CAR-T therapy. On February 23, 2024, the patient received a transfusion of Inaticabtagene Autoleucel Injection. Just one month after the transfusion, she achieved complete remission (CR) and minimal residual disease (MRD) negativity. Currently, the patient is recovering well and is about to return to school.

Professional Care from the Medical Team

Throughout the treatment, the expert team at The First Affiliated Hospital of Chongqing Medical University demonstrated exceptional medical skills and meticulous care. Professor Li noted that after multiple treatment failures, the patient chose the innovative therapy of Inaticabtagene Autoleucel Injection, which ultimately yielded gratifying results. During the CAR-T transfusion, the medical team closely monitored the patient’s condition, ensuring the safety and effectiveness of the treatment. The patient’s positive attitude and family support also laid the foundation for successful treatment.

Support from Commercial Insurance

This treatment not only relied on advanced medical technology but also benefited from the support of the patient’s family’s commercial insurance. During the treatment, the patient’s family actively applied for commercial insurance claims and successfully obtained full compensation, significantly reducing the financial burden. The support from commercial insurance increased the accessibility of the treatment, providing solid backing for the patient’s recovery.

Future Prospects

The approval of Inaticabtagene Autoleucel Injection has brought new hope to B-ALL patients, especially young ones. The excellent efficacy and safety of CAR-T therapy will significantly improve their quality of life. With more successful cases emerging, CAR-T therapy is expected to become the new standard for B-ALL treatment.

The successful case at The First Affiliated Hospital of Chongqing Medical University not only showcases the immense potential of Inaticabtagene Autoleucel Injection in treating leukemia but also provides valuable experience and reference for future clinical applications. The patient’s recovery journey is inspiring, symbolizing not only physical recovery but also a rebirth of the spirit.

Conclusion

The successful application of CAR-T therapy has shown leukemia patients a light of recovery. The professional team at The First Affiliated Hospital of Chongqing Medical University will continue to promote this innovative therapy, bringing hope and new life to more patients. With the advancement of medical technology and the support of commercial insurance, the future of patients will be even brighter.

🎉🎉To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!
WhatsApp: +8613717959070
Email: doctor.huang@globecancer.com

#CARTherapy #LeukemiaTreatment #InnovativeMedicine #ChongqingMedicalUniversity #MedicalBreakthrough #NewLife #CommercialInsurance #PatientRecovery #CancerTreatment #MedicalTechnology #PatientStory #MedicalAdvancement #HopeAndHealing #ChineseHealthcare #CARTTreatment #PhALL #HealthyFuture

12 months ago CAR-T

Haematologica Spotlight：A Chinese team published the largest-scale pediatric-style regimen treatment for adult Ph-negative ALL

🔬 Haematologica Spotlight 🔬

A Chinese team published the largest-scale pediatric-style regimen treatment for adult Ph-negative ALL

Acute Lymphoblastic Leukemia (ALL)

is a hematological malignancy characterized by the proliferation of immature lymphoid cells in the bone marrow, peripheral blood, and extramedullary sites. While the prognosis for childhood ALL is relatively favorable, with a 5-year overall survival rate of 80-90%, adult ALL poses greater challenges. Approximately 20-30% of adult acute leukemias are ALL, with about two-thirds being Philadelphia chromosome-negative (Ph-negative) ALL. Conventional adult ALL treatments have shown high remission rates but also high relapse rates and poor long-term survival.

Haematologica

Inspired by the success of pediatric ALL treatments, especially in adolescent and young adult patients, the Hematology Center at the

Chinese Academy of Medical Sciences and Peking Union Medical College Hospital

embarked on a groundbreaking journey. Their pioneering research, recently published in *Haematologica*, presents the results of the largest prospective cohort study in China investigating the efficacy of a pediatric-inspired regimen in adult Ph-negative ALL patients.

The study, led by Dr. Wang Jianxiang and his team,

evaluated the IH-2014 regimen’s effectiveness in 415 newly diagnosed adult Ph-negative ALL patients treated between April 2014 and December 2021, with a median age of 27 years (range 14-65 years) and a median follow-up of 40.8 months. The overall 5-year overall survival (OS) and disease-free survival (DFS) rates were 53.8% and 51.1%, respectively, with a chemotherapy-related mortality rate of 3.6%.

Patients achieving complete remission (CR)

after induction therapy with available bone marrow minimal residual disease (MRD) data were categorized based on diagnostic risk: standard-risk (SR) MRD-negative (<0.01%) in 73 patients (18.8%), SR MRD-positive (≥0.01%) in 69 patients (17.7%), high-risk (HR) MRD-negative in 120 patients (30.8%), and HR MRD-positive in 127 patients (32.6%). The 5-year OS rates for these groups were 82.6%, 58.7%, 58.3%, and 36.1%, respectively (P＜0.001), with corresponding cumulative relapse rates of 24.2%, 41.1%, 36.3%, and 50.1% (P＜0.001). Multivariate analysis identified age ≥40 years and MRD positivity after induction as independent adverse prognostic factors for OS and DFS.

In conclusion, the IH-2014 regimen demonstrates significant efficacy and good tolerability in adult Ph-negative ALL patients, with younger patients (<40 years) benefiting more prominently. Induction treatment response combined with MRD levels serves as a valuable prognostic indicator for long-term survival and relapse, guiding allogeneic hematopoietic stem cell transplantation decisions in patients achieving first complete remission (CR1).

This study marks a pivotal milestone in advancing adult ALL treatment strategies, showcasing China’s remarkable progress in the field of hematology. Stay tuned for more groundbreaking research from our team!

🎉To assess whether the condition is suitable for CAR-T therapy, you can submit Advanced Medicine in China for preliminary evaluation!

Email: doctor.huang@globecancer.com,

WhatsApp: +8613717959070

🌟 #Haematologica #LeukemiaTreatment #PediatricInspiration #ALL #AcuteLymphoblasticLeukemia #LymphoblasticLeukemia #Leukemia

1 year ago CAR-T

Breakthrough CAR-T Cell Therapy for R/R B-Cell ALL: A Game-Changer in Chinese Medical Innovation

Breakthrough CAR-T Cell Therapy for R/R B-Cell ALL: A Game-Changer in Chinese Medical Innovation

ALL- Acute Lymphoblastic Leukemia

The Fourth China Hematology Development Conference – CAR-T Frontier Forum and the First CAR-T Cell Immunotherapy Summit (JCIS), held on January 5, 2024, in Tianjin.

Potential Best-in-Class: Inaticabtagene Autoleucel Redefining Long-term Outcomes for R/R B-ALL

Professor Ma Jun from the Harbin Institute of Hematology and Oncology shared notable progress in immunotherapy and cell treatment for Chinese ALL. Previously, the overall complete response (CR) rate for adult R/R ALL treatment in China was approximately 40%, with a mere 11% 3-year survival rate. The introduction of CAR-T cell therapy has been a paradigm shift, altering the long-term outcomes for R/R B-ALL patients.

Inaticabtagene Autoleucel demonstrates superior efficacy:

Higher overall response rates (ORR) at 3 months and beyond, with median duration of response (DOR) and overall survival (OS) surpassing other products.

Patients treated with Inaticabtagene Autoleucel exhibit similar long-term benefits in OS, whether or not they undergo subsequent transplantation.

Inaticabtagene Autoleucel boasts enhanced safety:

Lower incidence rates of grade 3 cytokine release syndrome (CRS), grade 3 immune effector cell-associated neurotoxicity syndrome (ICANS), and infusion-related mortality compared to other CAR-T products.

Moreover, in minimal residual disease-positive (MRD+) B-ALL patients, CAR-T cell therapy has shown significant progress. It eradicates MRD, improves survival rates, and may serve as a first-line consolidation therapy for CR patients, aiding in:

Higher remission rates

Reduced transplant requirements, mitigating transplant-related complications

Maintenance of long-term remission for those unsuitable for allo-HSCT or unwilling to undergo it

Improved overall survival

Lower intensity and duration of intensive chemotherapy, leading to shorter treatment times and enhanced compliance.

The Future Outlook: Believing in the potential of CAR-T cell therapy, it is anticipated that this innovative treatment will extend hope to currently incurable diseases such as solid tumors and brain tumors. The strides made in Chinese medical innovation, exemplified by Inaticabtagene Autoleucel, signal a promising future for the global landscape of CAR-T cell therapy.

#CARTRevolution #InaticabtageneAutoleucel #HematologicCancerTherapy #ClinicalBreakthrough #ChinaHematologyConference #JCIS #BAllTreatment #MedicalAdvancements #CancerResearch #TreatmentInnovation #InaticabtageneAutoleucel #Autoleucel #ChineseCART #CARTTherapy #cancer #Bloodcancer #MedicineinCHINA #Medicaltourismo #Advancedmedicine #cancertherapy #leukemia

Menu

Tags Archives: Acute Lymphoblastic Leukemia